Arabian Health Care Supply CO Pharmaceutical Import Profile — Saudi Arabia (DGFT 2022–2026)

Name: Arabian Health Care Supply CO Pharmaceutical Import Records from India — 2 Products, $406.4K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Arabian Health Care Supply CO — Pharmaceutical Importer Profile (2026) | 2 Products, $406.4K Trade | TransData Nexus

Arabian Health Care Supply CO

Pharmaceutical Importer · Saudi Arabia · Advanced Oncology Focus · $406.4K Total Trade · DGFT Verified

Arabian Health Care Supply CO is a pharmaceutical importer based in Saudi Arabia with a total trade value of $406.4K across 2 products in 1 therapeutic categories. Based on 12 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Arabian Health Care Supply CO sources from 1 verified Indian supplier, with Emcure Pharmaceuticals Limited accounting for 100.0% of imports.

Arabian Health Care Supply CO — Import Portfolio & Supplier Network

Arabian Health Care Supply CO import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Arabian Health Care Supply CO?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Emcure Pharmaceuticals Limited	$1.2M	53	100.0%

Arabian Health Care Supply CO sources from 1 verified Indian supplier across 40 distinct formulations. The sourcing is highly concentrated — Emcure Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Pharma: cidofovir injection 375MG/5ML	$150.0K	3
Pharma: bicnu 100MG injection	$134.8K	5
Pharmaceuticals products( finished product): megval 50 MG INJ 1 vial(melphalan hydrochloride for injection 50MG/vial)	$94.7K	2
Pharma: megval injection (melphalan	$86.0K	3
Pharma prod finished prod generic name phenylephrine hcl 10 MG INJ 10x1 vial phenylephrine hcl injection 10MG ML	$50.0K	1
Pharmaceutical article / ods / product / item finished product - bicnu 100 MG INJ 1 vial carmustinefor injection USP 100MG	$50.0K	1
Pharma: imtus 100 MG injection (irinotecan hydrochloride injection 100MG/5ML)-1vial(inv.no.: 2402300696 dt. 07.02.2024	$50.0K	1
Pharmaceuticals products finished product bicnu 100 MG INJ 1 vial carmustine forinjection USP 100MG	$50.0K	1
Pharma products(finished product)(generic name)phenylephrine hcl 10MG INJ 10x1 vial( phenylephrine hcl injection 10MG/ML	$49.8K	1
Pharma: imtus 100 MG injection	$46.7K	1
Pharma: megval 50MG injectionmelphalanhydrochloride for injection 50MG/vial-1vialinv.no.: 2309300305 dt.	$45.3K	2
Pharmaceuticals products ( finished product) phenylephrine hcl 10 MG INJ 10x1 vial (phenylephrine hcl injection 10MG/ML	$41.0K	1
Pharma: bicnu 100MG injection carmustine for injection USP 100 MG - 1 vial document no.: 2309300320 dt.	$37.3K	1
Imtus 100 MG INJ 1 vial irinotecan hydrochloride injection 100MG 5ML b no ela1ah5001 mfg 01 05 2025 exp 30 04	$34.4K	1
Pharma : cidofovir 375MG injection (cidofovir injection 375MG/5ML(75MG/ML)) - 1vial (inv.no.: 2403300839 dt. 21.03.2024)	$34.4K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Melphalan	Advanced Oncology	$232.7K	8	1.8%	9
2	Carmustine	Advanced Oncology	$173.7K	4	0.8%	10

Arabian Health Care Supply CO imports 2 pharmaceutical products across 1 categories into Saudi Arabia totaling $406.4K.

Arabian Health Care Supply CO — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Arabian Health Care Supply Company (AHCSC), established in 1979, is a prominent distributor of medical and pharmaceutical products in Saudi Arabia. Headquartered in Riyadh, the company operates under the auspices of the Olayan Group, a private multinational enterprise with diverse commercial and industrial interests across the Middle East. AHCSC's extensive product portfolio includes medical equipment, pharmaceuticals, and critical care products, sourced from renowned international partners. The company has offices in major cities throughout Saudi Arabia, offering full geographical coverage.

2Distribution Network

AHCSC's distribution network spans key regions in Saudi Arabia, with offices in Riyadh, Al Khobar, and Dammam. The Riyadh headquarters is located at Olayan Plaza, Al Ahsa Street, Malaz District. The Al Khobar branch is situated at 86G3+7VG, King Fahd Road, Al Jawharah, Al Khobar 34431. The Dammam branch is located at C523+8VW, Al Khalidiyyah Al Janubiyyah, Dammam 32226. This strategic positioning enables AHCSC to effectively serve the diverse healthcare needs across the Kingdom.

3Industry Role

AHCSC plays a pivotal role in Saudi Arabia's pharmaceutical supply chain as a primary wholesaler and distributor. The company sources a wide array of medical and pharmaceutical products from international manufacturers, including robotic systems, pharmacy automation systems, renal equipment, capital equipment, implantable prostheses, medical disposables, and critical care products used in CCUs and operating rooms. By bridging the gap between global suppliers and local healthcare providers, AHCSC ensures the timely availability of essential medical products throughout the Kingdom.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Arabian Health Care Supply CO

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

AHCSC's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, Emcure Pharmaceuticals Limited. This dependency suggests a strategic choice to maintain a streamlined supply chain and potentially leverage favorable terms with a key supplier. However, the limited number of suppliers may pose risks related to supply chain disruptions, pricing fluctuations, and dependency on a single source. The stability of this relationship is crucial for AHCSC's operations, and any changes in Emcure's production capacity, pricing, or regulatory compliance could directly impact AHCSC's ability to meet market demand.

2Supply Chain Resilience

The resilience of AHCSC's supply chain is closely tied to its reliance on Emcure Pharmaceuticals Limited. While this focused sourcing strategy may offer operational efficiencies, it also exposes AHCSC to potential vulnerabilities. The absence of backup suppliers for its imported pharmaceutical products indicates a lack of diversification, which could be problematic in the event of supply disruptions, regulatory changes, or geopolitical issues affecting India. Additionally, the concentration on a single supplier may limit AHCSC's ability to negotiate better terms or adapt to changing market conditions.

Importing Pharmaceuticals into Saudi Arabia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Saudi Arabia

1Regulatory Authority & Framework

The Saudi Food and Drug Authority (SFDA) is the primary regulatory body overseeing the safety, efficacy, and quality of pharmaceutical products in Saudi Arabia. The SFDA enforces the Law of Pharmaceutical Establishments and Products (2023), which governs the manufacturing, importing, exporting, registration, and marketing authorization of medicinal products. This comprehensive legislation ensures that all pharmaceutical products meet stringent standards before entering the Saudi market.

2Import Licensing & GMP

Importing pharmaceutical products into Saudi Arabia requires obtaining an import license from the Ministry of Health. Additionally, a Certificate of Free Sale and a certificate of analysis are mandatory for pharmaceutical imports. These documents verify that the products are authorized for sale in the exporting country and meet specific quality standards. The SFDA also requires that manufacturing facilities adhere to Good Manufacturing Practice (GMP) standards, which are recognized internationally, including EU GMP, WHO GMP, and PIC/S certifications. Compliance with these standards is essential for obtaining the necessary import approvals.

3Quality & Labeling

Arabian Health Care Supply CO — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

AHCSC's focus on importing pharmaceutical products within the Advanced Oncology therapeutic category indicates a strategic alignment with the growing demand for cancer treatments in Saudi Arabia. The significant import values of Melphalan and Carmustine suggest that AHCSC is addressing critical needs in oncology care. This product strategy positions AHCSC as a key supplier of essential oncology medications, catering to the needs of healthcare providers and patients requiring these treatments.

2Sourcing Profile

AHCSC's sourcing strategy emphasizes the importation of generic drugs, particularly in the oncology therapeutic area. The company's preference for finished pharmaceutical formulations, such as tablets and injections, aligns with the immediate needs of healthcare providers and patients. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable source for these products, ensuring a reliable supply chain for AHCSC.

3Market Positioning

Based on its product mix, AHCSC primarily serves the hospital and healthcare provider segments in Saudi Arabia. The focus on critical care products and oncology medications positions the company as a key supplier to hospitals, clinics, and specialized medical centers that require these essential treatments. AHCSC's comprehensive distribution network ensures that these products are accessible across the Kingdom, supporting the healthcare infrastructure's needs.

Seller's Guide — How to Become a Supplier to Arabian Health Care Supply CO

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with AHCSC, particularly by offering alternative products or formulations that meet the company's requirements. Diversifying AHCSC's supplier base can enhance supply chain resilience and reduce dependency on a single source. Indian exporters can explore this opportunity by ensuring their products comply with SFDA regulations and meet the quality standards required for the Saudi market.

2Requirements & Qualifications

Indian exporters seeking to supply AHCSC and the Saudi Arabian market must ensure their products are registered with the SFDA and comply with the Law of Pharmaceutical Establishments and Products (2023). Manufacturing facilities should hold valid GMP certifications recognized by the SFDA, such as EU GMP, WHO GMP, or PIC/S. Additionally, products must meet labeling requirements, including Arabic language labeling and serialization mandates. Ensuring these qualifications will facilitate the importation process and market acceptance in Saudi Arabia.

3How to Approach

Frequently Asked Questions — Arabian Health Care Supply CO

What products does Arabian Health Care Supply CO import from India?

Arabian Health Care Supply CO imports 2 pharmaceutical products across 1 categories. Top imports: Melphalan ($232.7K), Carmustine ($173.7K).

Who supplies pharmaceuticals to Arabian Health Care Supply CO from India?

Arabian Health Care Supply CO sources from 1 verified Indian suppliers. The primary supplier is Emcure Pharmaceuticals Limited (100.0% of imports, $1.2M).

What is Arabian Health Care Supply CO's total pharmaceutical import value?

Arabian Health Care Supply CO's total pharmaceutical import value from India is $406.4K, based on 12 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Arabian Health Care Supply CO focus on?

Arabian Health Care Supply CO imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Arabian Health Care Supply CO Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.